The term liquid biopsy in the context of malignant diseases refers to various methodologies for the purpose of blood-based monitoring and genotyping of solid tumors with the advantage of being largely non-invasive as compared to tumor biopsies. Besides various assays for the determination and characterization of circulating tumor cells blood plasma-based assays for the genotyping of circulating cell-free DNA (cfDNA) and cfRNA of solid tumors have been entering the clinic. Key application of these assays are initial diagnosis, monitoring of response to treatment, and detection of minimal residual disease. Cutting-edge molecular technologies like Next-generation sequencing are the fundamental cornerstones of these innovative assays. The assays can detect genetic mutations in cancer-driving hotspot genes, tumor suppressor genes, gene copy number variations, as well as gene fusions. These genetic alterations are important molecular targets for personalized or precision medicine.
NextGen Oncology offers Oncomine™ Pan-Cancer cell-free assays. The Oncomine™ assay provides a comprehensive content for clinically relevant oncology molecule profiling.
Oncomine Pan-Cancer Cell-Free Assay
Hotspot genes
AKT1, ALK, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, RAF1, RET, ROS1, SF3B1, SMAD4, SMO
Tumor supressor genes
APC, FBXW7, PTEN, TP53
CNV genes
CCND1, CCND2, CCND3, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, MYC
Gene fusions
ALK, BRAF, ERG, ETV1, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK3, RET, ROS1
- 52 genes
- Single library from DNA and RNA
- 272 amplicons
- >900 hotspots and indels
- Extended coverage of TP53
- 96 fusions
- 12 CNVs
- MET exon 14 skipping
Within the framework of mutation targeted therapies, growing resistances are a common issue. The tumor resumes growing again. The reason for this is the occurrence of new mutations that necessitate updating the treatment plan. By using the new class of molecular assays, the therapeutically relevant status quo of the tumor can be determined in real-time at any given point to modify treatment as early as possible.
Test Requirements
20ml PaxGene tubes
Duration of Testing
Two weeks.